Baidu
map

上海392万老年人接种新冠疫苗,覆盖率67.42%,全程接种率63.16%

2022-06-20 上海卫健委 上海卫健委

老年人想接种新冠肺炎疫苗,却因行动不便无法自行到门诊接种,针对这一问题,在6月17日举行的上海市新冠肺炎疫情防控工作新闻发布会上,上海市卫生健康委副主任赵丹丹表示,上海各区在开放社区接种门诊的基础上,

老年人想接种新冠肺炎疫苗,却因行动不便无法自行到门诊接种,针对这一问题,在6月17日举行的上海市新冠肺炎疫情防控工作新闻发布会上,上海市卫生健康委副主任赵丹丹表示,上海各区在开放社区接种门诊的基础上,已经通过养老机构、重点社区上门服务等多种服务形式,因地制宜地不断优化接种服务模式。

赵丹丹说,考虑到老年人群中存在着“数字鸿沟”的问题,上海市有针对性地着手相关服务的适应性改进,倡导预防接种预约服务“数字无障碍”。对于不方便使用智能手机的老年人等特殊群体,可通过社区卫生服务中心的健康驿站自助终端刷身份证、社保卡后登记。今年4月,健康云升级新冠疫苗接种预约系统,作为线下现场预约、健康驿站预约的补充,老年人的家属或社区志愿者可通过健康云代为在线上预约新冠疫苗接种服务,这就增加了老年人接种疫苗的预约途径。

截至6月16日,上海全市60岁及以上老年人新冠疫苗累计接种约1011万剂,覆盖约392万人,覆盖率67.42%;全程接种约367万人,接种率63.16%。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2038130, encodeId=96cd203813094, content=<a href='/topic/show?id=d26690569a5' target=_blank style='color:#2F92EE;'>#覆盖率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90569, encryptionId=d26690569a5, topicName=覆盖率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca772500164, createdName=ms1490123962508630, createdTime=Mon Apr 24 12:25:46 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078684, encodeId=36e220e868434, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Nov 20 07:25:46 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227471, encodeId=321a122e4710e, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Jun 20 07:10:43 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227467, encodeId=ecd0122e4671c, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Mon Jun 20 06:47:32 CST 2022, time=2022-06-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2038130, encodeId=96cd203813094, content=<a href='/topic/show?id=d26690569a5' target=_blank style='color:#2F92EE;'>#覆盖率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90569, encryptionId=d26690569a5, topicName=覆盖率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca772500164, createdName=ms1490123962508630, createdTime=Mon Apr 24 12:25:46 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078684, encodeId=36e220e868434, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Nov 20 07:25:46 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227471, encodeId=321a122e4710e, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Jun 20 07:10:43 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227467, encodeId=ecd0122e4671c, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Mon Jun 20 06:47:32 CST 2022, time=2022-06-20, status=1, ipAttribution=)]
    2022-11-20 gous
  3. [GetPortalCommentsPageByObjectIdResponse(id=2038130, encodeId=96cd203813094, content=<a href='/topic/show?id=d26690569a5' target=_blank style='color:#2F92EE;'>#覆盖率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90569, encryptionId=d26690569a5, topicName=覆盖率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca772500164, createdName=ms1490123962508630, createdTime=Mon Apr 24 12:25:46 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078684, encodeId=36e220e868434, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Nov 20 07:25:46 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227471, encodeId=321a122e4710e, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Jun 20 07:10:43 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227467, encodeId=ecd0122e4671c, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Mon Jun 20 06:47:32 CST 2022, time=2022-06-20, status=1, ipAttribution=)]
    2022-06-20 学医无涯

    了解一下

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2038130, encodeId=96cd203813094, content=<a href='/topic/show?id=d26690569a5' target=_blank style='color:#2F92EE;'>#覆盖率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90569, encryptionId=d26690569a5, topicName=覆盖率)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca772500164, createdName=ms1490123962508630, createdTime=Mon Apr 24 12:25:46 CST 2023, time=2023-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078684, encodeId=36e220e868434, content=<a href='/topic/show?id=a34956696a7' target=_blank style='color:#2F92EE;'>#接种率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56696, encryptionId=a34956696a7, topicName=接种率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a9987, createdName=gous, createdTime=Sun Nov 20 07:25:46 CST 2022, time=2022-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227471, encodeId=321a122e4710e, content=了解一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Mon Jun 20 07:10:43 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227467, encodeId=ecd0122e4671c, content=认真学习~~, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cfb41991958, createdName=xulv123, createdTime=Mon Jun 20 06:47:32 CST 2022, time=2022-06-20, status=1, ipAttribution=)]
    2022-06-20 xulv123

    认真学习~~

    0

相关资讯

莫德纳第二代mRNA新冠疫苗,针对奥密克戎中和抗体水平较加强针提高1.75倍

美国 mRNA 新冠疫苗研发企业莫德纳(Moderna)在官网发布其奥密克戎(Omicron )二价新冠候选疫苗 mRNA-1273.214 加强针的最新临床数据。

BMJ:同源、异源新冠疫苗接种效果大比较

根据世界卫生组织于 2022 年 4 月 5 日发布的 covid-19 每周流行病学更新,由 SARS-CoV-2 引起的 covid-19 大流行已导致全球超过 4.89 亿例确诊病例和 600

上海3-17岁未成年人新冠疫苗接种覆盖率77.62%

在6月19日召开的上海市新冠肺炎疫情防控工作新闻发布会上,上海市卫生健康委副主任赵丹丹通报,截至6月18日,上海市3-17岁未成年人新冠疫苗累计接种345.66万剂,覆盖180.51万人,覆盖率77.

NEJM:新冠病毒感染以后还需要不需要接种疫苗?

尽管在几项研究中观察到两剂 BNT162b2 疫苗 (Pfizer-BioNTech) 后对严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 感染的保护下降,1-3 但保护水平仍不清楚,正

FDA委员会全票支持!辉瑞、Moderna新冠疫苗幼儿适应症即将获批

当地时间6月15日,美国食品和药品管理局(FDA)疫苗与相关生物制品咨询委员会(VRBPAC)21名成员全部投票赞成:FDA授权批准辉瑞和Moderna针对幼儿适应症的新冠疫苗,预计FDA将在未来几天

美国FDA顾问小组考虑是否将莫德纳新冠疫苗用于6至17岁人群

美国食品药品监督管理局(FDA)的一个顾问小组将在当地时间周二举行会议,考虑是否应将莫德纳新冠疫苗的使用范围扩大到6至17岁的儿童和青少年。

Baidu
map
Baidu
map
Baidu
map